Recombinant Human TWEAK/TNFSF12 Protein, CF | R&D Systems 1090-TW-025/CF product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human TWEAK/TNFSF12 Protein, CF

catalog :

1090-TW-025/CF

quantity :

25 ug

price :

432 USD

citations: 16

Reference
Vesting A, Jais A, Klemm P, Steuernagel L, Wienand P, Fog Tonnesen M, et al. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition. Mol Metab. 2022;66:101626 pubmed publisher
G xfc ner G, A xdf falg M, Zhao K, Dreyer T, Lahiri S, Lo Y, et al. Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity. EMBO Mol Med. 2022;14:e16084 pubmed publisher
Badia Villanueva M, Defaus S, Foj R, Andreu D, Oliva B, Sierra A, et al. Evaluation of Computationally Designed Peptides against TWEAK, a Cytokine of the Tumour Necrosis Factor Ligand Family. Int J Mol Sci. 2021;22: pubmed publisher
Wang X, Cheng D, Hu G, Liang L, Tan F, Xiao T, et al. Tumor Necrosis Factor (TNF) Receptor Expression Determines Keratinocyte Fate upon Stimulation with TNF-Like Weak Inducer of Apoptosis. Mediators Inflamm. 2019;2019:2945083 pubmed publisher
Lee S, Kim J, Ko J, Lee E, Koh H, Yoon J. Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves' orbital fibroblasts. PLoS ONE. 2018;13:e0209583 pubmed publisher
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher
Xue L, Liu L, Huang J, Wen J, Yang R, Bo L, et al. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Activates Type I Interferon Signals in Lupus Nephritis. Biomed Res Int. 2017;2017:4927376 pubmed publisher
Brightbill H, Suto E, Blaquiere N, Ramamoorthi N, Sujatha Bhaskar S, Gogol E, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018;9:179 pubmed publisher
Sidler D, Wu P, Herro R, Claus M, Wolf D, Kawakami Y, et al. TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. Nat Commun. 2017;8:15395 pubmed publisher
Wang A, Zhang F, Xu H, Xu M, Cao Y, Wang C, et al. TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-?B/STAT3 pathways. Mol Immunol. 2017;87:67-75 pubmed publisher
Yamaguchi N, Nakayama Y, Yamaguchi N. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 2017;292:8136-8148 pubmed publisher
Guicciardi M, Krishnan A, Bronk S, Hirsova P, Griffith T, Gores G. Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. Cell Death Dis. 2017;8:e2535 pubmed publisher
Xu M, Zhang F, Wang A, Wang C, Cao Y, Zhang M, et al. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Promotes Hepatic Stellate Cells Migration via Canonical NF-?B/MMP9 Pathway. PLoS ONE. 2016;11:e0167658 pubmed publisher
Gurunathan S, Winkles J, Ghosh S, Hayden M. Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation. J Biol Chem. 2014;289:12976-88 pubmed publisher
Zhou H, Ekmekcioglu S, Marks J, Mohamedali K, Asrani K, Phillips K, et al. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2013;133:1052-62 pubmed publisher
Gaudineau B, Fougere M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion. J Cell Sci. 2012;125:4475-86 pubmed publisher

product information

master code :

1090-TW/CF

SKU :

1090-TW-025/CF

product name :

Recombinant Human TWEAK/TNFSF12 Protein, CF

unit size :

25 ug

description :

The Recombinant Human TWEAK/TNFSF12 Protein, CF from R&D Systems is derived from E. coli. The Recombinant Human TWEAK/TNFSF12 Protein, CF has been validated for the following applications: Bioactivity.

target :

TWEAK/TNFSF12

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

theoretical molecular weight :

18.3 kDa

gene symbol :

TNFSF12

details of functionality :

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 0.200-4.00 ng/mL.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

top caption :

Recombinant Human TWEAK/TNFSF12 Protein Bioactivity

accessionNumbers :

Q4ACW9

applications :

Bioactivity

source long :

E. coli -derived human TWEAK/TNFSF12 protein Arg93-His249, with an N-terminal Met and 6-His tag

source short :

E. coli

USD :

432 USD

alt names :

APO3 ligand, APO3LMGC20669, DR3LGTWEAKAPO3/DR3 ligand, MGC129581, TNF-related weak inducer of apoptosis, TNFSF12, tumor necrosis factor (ligand) superfamily, member 12, tumor necrosis factor ligand superfamily member 12

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.